...
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy.
【24h】

Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy.

机译:表皮生长因子受体作为术前放化疗治疗的局部晚期直肠癌患者肿瘤降级的预测因子。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To examine retrospectively whether levels of epidermal growth factor receptor (EGFR) expression can predict tumor downstaging after preoperative chemoradiotherapy in patients with locally advanced rectal cancer. METHODS AND MATERIALS: A total of 183 patients with rectal cancer (cT3-T4 or N+) were enrolled in this study. Preoperative chemoradiotherapy consisted of 50.4 Gy of pelvic radiation with concurrent 5-fluorouracil and leucovorin bolus intravenous chemotherapy in 94 patients or oral capecitabine and leucovorin in 89 patients. EGFR expression in pretreatment paraffin-embedded tumor biopsy specimens was assessed by immunohistochemistry. EGFR expression was determined from the intensity and extent of staining. Tumor downstaging was defined as a reduction of at least one T-stage level. RESULTS: Tumor downstaging occurred in 97 patients (53%), and the tumors showed a pathologic complete response in 27 patients (15%). Positive EGFR expression was observed in 140 (76%) of 183 patients. EGFR expression levels were low in 113 patients (62%) and high in 70 patients (38%). On logistic regression analysis, the significant predictive factor for increased tumor downstaging was a low level of EGFR expression and preoperative chemotherapy using oral capecitabine (odds ratio, 0.437; p = 0.012 vs. odds ratio, 3.235; p < 0.001, respectively). CONCLUSION: A high level of EGFR expression may be a significant predictive molecular marker for decreased tumor downstaging after preoperative chemoradiotherapy in locally advanced rectal cancer.
机译:目的:回顾性研究表皮生长因子受体(EGFR)的表达水平是否可以预测局部晚期直肠癌患者术前放化疗后肿瘤的分期。方法和材料:本研究共纳入183例直肠癌(cT3-T4或N +)患者。术前放化疗由50.4 Gy的盆腔放疗,94例患者同时进行5-氟尿嘧啶和亚叶酸静脉推注组成,或89例患者口服卡培他滨和亚叶酸。通过免疫组织化学评估预处理石蜡包埋的肿瘤活检标本中的EGFR表达。从染色的强度和程度确定EGFR的表达。肿瘤降级被定义为至少降低一个T期水平。结果:97例患者(53%)发生肿瘤分期降低,27例患者(15%)表现出病理完全缓解。在183例患者中有140例(76%)观察到了EGFR阳性表达。 EGFR表达水平在113例患者中低(62%),在70例患者中高(38%)。在逻辑回归分析中,肿瘤分期降低的重要预测因素是EGFR表达水平低和口服卡培他滨的术前化疗水平(几率分别为0.437; p = 0.012 vs.优势比为3.235; p <0.001)。结论:高水平的EGFR表达可能是局部晚期直肠癌术前放化疗后降低肿瘤分期的重要预测分子标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号